N-(3-cyanophenyl)-2-nitrobenzamide | 219519-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-cyanophenyl)-2-nitrobenzamide
• 英文别名: 2-nitro-N-(3-cyanophenyl)benzamide
• CAS: 219519-37-6
• 化学式: C₁₄H₉N₃O₃
• 分子量: 267.244
• InChiKey: BVOQUUMQLFPWRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-cyanophenyl)-2-nitrobenzamide 在 盐酸羟胺 、 铁粉 、 氯化铵 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 苯 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N2-Thiophenecarbonyl- and N2-Tosylanthranilamides

  摘要：

  凝血酶（因子IIa）和因子Xa（FXa）是内在和外在凝血途径交汇处的关键酶，也是开发新型抗凝药物中最具吸引力的药理学靶点。合成20种非脒基N2-噻酚羰基-和N2-对甲苯磺酰基邻氨基苯甲酰胺1-20以及6种脒基N2-噻酚羰基-和N2-对甲苯磺酰基邻氨基苯甲酰胺21-26，以评估它们在体外以30µg/mL浓度下对人血浆的活化部分凝血活酶时间（aPTT）和凝血酶原时间（PT）。结果，选择了化合物5、9和21-23进一步研究其抗血栓活性。5、9和21-23的抗凝特性显著表现为体外PT和aPTT的浓度依赖性延长、体内出血时间延长以及体外凝血时间延长。这些化合物浓度依赖性地抑制了凝血酶和FXa的活性，并抑制了人内皮细胞中凝血酶和FXa的生成。此外，数据显示5、9和21-23显著抑制了凝血酶催化的纤维蛋白聚合和鼠标血小板聚集，以及体外和离体由U46619诱导的血小板聚集。在评估的衍生物中，N-(3'-脒基苯基)-2-((2''-噻吩基)羰基氨基)苯甲酰胺（21）是最活跃的化合物。

  DOI：

  10.3390/ijms18061144
• 作为产物：
  描述：

  邻硝基苯甲酸 在 草酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-(3-cyanophenyl)-2-nitrobenzamide
  参考文献：
  名称：

  Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N2-Thiophenecarbonyl- and N2-Tosylanthranilamides

  摘要：

  凝血酶（因子IIa）和因子Xa（FXa）是内在和外在凝血途径交汇处的关键酶，也是开发新型抗凝药物中最具吸引力的药理学靶点。合成20种非脒基N2-噻酚羰基-和N2-对甲苯磺酰基邻氨基苯甲酰胺1-20以及6种脒基N2-噻酚羰基-和N2-对甲苯磺酰基邻氨基苯甲酰胺21-26，以评估它们在体外以30µg/mL浓度下对人血浆的活化部分凝血活酶时间（aPTT）和凝血酶原时间（PT）。结果，选择了化合物5、9和21-23进一步研究其抗血栓活性。5、9和21-23的抗凝特性显著表现为体外PT和aPTT的浓度依赖性延长、体内出血时间延长以及体外凝血时间延长。这些化合物浓度依赖性地抑制了凝血酶和FXa的活性，并抑制了人内皮细胞中凝血酶和FXa的生成。此外，数据显示5、9和21-23显著抑制了凝血酶催化的纤维蛋白聚合和鼠标血小板聚集，以及体外和离体由U46619诱导的血小板聚集。在评估的衍生物中，N-(3'-脒基苯基)-2-((2''-噻吩基)羰基氨基)苯甲酰胺（21）是最活跃的化合物。

  DOI：

  10.3390/ijms18061144

文献信息

• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US06417200B1

  公开（公告）日：2002-07-09

  This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  这种应用涉及到式(I)的化合物，该化合物的药用盐或其前药，如本文所定义的，以及其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备方法和中间体。
• N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20020019414A1

  公开（公告）日：2002-02-14

  1 Described are compounds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 -(CH 2 )n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 1 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y═SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  描述的是化合物的结构式（I），其中W是O或S；X是NR8；Y是CR9R10-(CH2)n，其中R9和R10彼此独立地是氢或较低的烷基，n是从0到3的整数；或Y是SO2；R1是芳基；R2是一个含有一个或多个环氮原子的单环或双环杂环基团，但R2不能代表2-邻苯二甲酰胺，并且在Y为SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任何一个，独立于其他，是H或除氢之外的取代基；R7和R8，彼此独立地是H或较低的烷基；或其N-氧化物或药用可接受的盐，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制产生反应的恶性疾病的药物产品。结构式（I）的化合物可用于治疗恶性疾病，如肿瘤疾病，视网膜病和老年性黄斑变性等。
• N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20040198782A1

  公开（公告）日：2004-10-07

  1 Described are compunds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 —(CH 2 ) n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 2 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y=SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  描述了化合物的公式(I)，其中W为O或S; X为NR8; Y为CR9R10—(CH2)n，其中R9和R10独立地为氢或低烷基，n为0至3的整数，包括0和3; 或Y为SO2; R2为芳基; R2为一种单环或双环杂环芳基，包括一个或多个环氮原子，但R2不能表示2-邻苯二甲酰亚胺基，且在Y = SO2的情况下不能表示2,1,3-苯并噻二唑-4-基; R3、R4、R5和R6中的任何一个，除了氢之外，都是取代基; R7和R8独立地为氢或低烷基; 或其N-氧化物或药学上可接受的盐，用于制备治疗对VEGF受体酪氨酸激酶活性抑制有反应的肿瘤疾病的制药产品。公式(I)的化合物可用于治疗肿瘤疾病，如肿瘤疾病，视网膜病和年龄相关性黄斑变性等。
• N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20030064992A1

  公开（公告）日：2003-04-03

  1 Described are compunds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 —(CH 2 )n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 1 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y=SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  本文描述了式(I)的化合物，其中W为O或S；X为NR8；Y为CR9R10—(CH2)n，其中R9和R10独立地为氢或低碳基，n为0至3的整数，或Y为SO2；R1为芳基；R2为一个单环或双环杂芳基，其中包含一个或多个环氮原子，但R2不能代表2-苯酰亚胺基，且在Y=SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任意一个，独立于其他的，为H或除氢以外的取代基；且R7和R8独立地为H或低碳基；或其N-氧化物或药学上可接受的盐，用于制备治疗对VEGF受体酪氨酸激酶活性抑制有反应的肿瘤疾病的药物产品。式(I)的化合物可用于治疗肿瘤疾病，如肿瘤疾病、视网膜病变和老年性黄斑变性等。
• Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa:  Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity
  作者：Michael R. Wiley、Leonard C. Weir、Steven Briggs、Nancy A. Bryan、John Buben、Charles Campbell、Nickolay Y. Chirgadze、Richard C. Conrad、Trelia J. Craft、James V. Ficorilli、Jeffry B. Franciskovich、Larry L. Froelich、Donetta S. Gifford-Moore、Theodore Goodson、David K. Herron、Valentine J. Klimkowski、Kenneth D. Kurz、Jeffery A. Kyle、John J. Masters、Andrew M. Ratz、Guy Milot、Robert T. Shuman、Tommy Smith、Gerald F. Smith、Ann Louise Tebbe、Jennifer M. Tinsley、Richard D. Towner、Alexander Wilson、Ying K. Yee

  DOI：10.1021/jm9903287

  日期：2000.3.1

  To enhance the potency of 1,2-dibenzamidobenzene-derived inhibitors of factor Xa (fXa), an amidine substituent was incorporated on one of the benzoyl side chains to interact with Asp189 in the S1 specificity pocket. Lead molecule 1 was docked into the active site of Ma to facilitate inhibitor design. Subsequently, iterative SAR studies and molecular modeling led to a 1000-fold increase in Ma affinity and a refined model of the new inhibitors in the Ma active site. Strong support for the computational model was achieved through the acquisition of an X-ray crystal structure using thrombin as a surrogate protein. The amidines in this series show high levels of selectivity for the inhibition of Ma relative to other trypsin-like serine proteases. Furthermore, the Ma affinity of compounds in this series (K-ass = 50-500 x 10(6) L/mol) translates effectively into both anticoagulant activity in vitro and antithrombotic activity in vivo.